SCHEMBL1906786

SCHEMBL1906786

O=C1C(=O)[C@@H](O)[C@H](O)[C@@H](O)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6300746 0.85 KDM4E (0.31)
SCHEMBL14441612 0.77 KDM4E (0.31)
SCHEMBL22939433 0.77 LMNA (0.36)
SCHEMBL649183 0.68
SCHEMBL3670357 0.67
SCHEMBL29948439 0.64
SCHEMBL9513293 0.63
SCHEMBL11213847 0.62
SCHEMBL5953737 0.62 IDUA (0.42)
SCHEMBL4165018 0.62 LMNA (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4355740-A1 METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS Global Biolife Inc. (US) 2024-04-24 EP disclosed
WO-2023212487-A1 METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS GLOBAL BIOLIFE INC. (US) 2023-11-02 WO disclosed
US-20220401403-A1 METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS GLOBAL BIOLIFE INC. 2022-12-22 US disclosed
WO-2022265925-A1 METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS GLOBAL BIOLIFE INC. (US) 2022-12-22 WO disclosed
US-20220249530-A1 METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS GLOBAL BIOLIFE INC. 2022-08-11 US disclosed
US-11311563-B2 Method and composition for preventing and treating viral infections GLOBAL BIOLIFE INC. (US) 2022-04-26 US disclosed
US-20210299088-A1 METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS GLOBAL BIOLIFE INC. 2021-09-30 US disclosed
US-11033528-B2 Method and composition for preventing and treating viral infections GLOBAL BIOLIFE INC. (US) 2021-06-15 US disclosed
EP-2129371-B1 COMPOSITION FOR TREATING DIABETES AND METABOLIC DISORDERS WITH QUERCETIN, MYRCETIN AND CHLOROGENIC ACID ATM METABOLICS LLLP (US) 2021-05-05 EP disclosed
US-20200306281-A1 METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS GLOBAL BIOLIFE INC. 2020-10-01 US disclosed
US-20140031420-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM Metabolics LLC (US) 2014-01-30 US disclosed
US-20120252887-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM METABOLICS LLLP (US) 2012-10-04 US disclosed
US-8198319-B2 Composition and method for treating diabetes and metabolic disorders ATM METABOLICS, LLC 2012-06-12 US disclosed
US-8034838-B2 Composition and method for the treatment of neurological disorders GLOBAL BIOLIFE, INC. 2011-10-11 US disclosed
US-20110118345-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM METABOLICS, LLC 2011-05-19 US disclosed
US-7943164-B2 Contains quercetin, myricetin and chlorogenic acid; weight loss and weight control; inhibiting glucose absorption in the gut, enhancing glucose absorption by muscle tissue, inhibiting carbohydrate transport, inhibiting glucose/fat storage and inhibiting the manufacture of glucose by the liver ATM METABOLICS, LLC 2011-05-17 US disclosed
EP-2129371-A1 COMPOSITION FOR TREATING DIABETES AND METABOLIC DISORDERS WITH QUERCETIN, MYRCETIN AND CHLOROGENIC ACID ATM Metabolics LLLP (US) 2009-12-09 EP disclosed
US-20090298932-A1 COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS GLOBAL BIOLIFE, INC. 2009-12-03 US disclosed
WO-2008115723-A1 COMPOSITION FOR TREATING DIABETES AND METABOLIC DISORDERS WITH QUERCETIN, MYRCETIN AND CHLOROGENIC ACID ATM METABOLICS LLLP (US) 2008-09-25 WO disclosed
US-20080234364-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM METABOLICS, LLC 2008-09-25 US disclosed